Back to Results
First PageMeta Content
Chelating agents / Health / Deferiprone / Deferasirox / Thalassemia / Iron overload / Beta-thalassemia / Deferoxamine / Chelation therapy / Medicine / Chemistry / Antidotes


LC Paper No. CB[removed]) For Information On 24 June 2008 Legislative Council Panel on Health Services Iron chelating therapy for Thalassaemia patients
Add to Reading List

Document Date: 2008-06-20 03:55:54

Open Document

File Size: 97,65 KB

Share Result on Facebook

City

Atlanta / /

Company

Novartis / /

Country

United States / /

Currency

USD / /

Event

FDA Phase / /

Facility

Hospital Authority / /

IndustryTerm

pharmaceutical market / medical technology / /

MedicalCondition

chronic iron / cataracts / progressive hepatic fibrosis / neurological disorders / arthritis / local injection site disorder / chronic / thalassemia and other conditions / abdominal arthralgia / neutropenia / nausea / high-frequency hearing loss / skin rash / thrombocytopenia / concomitant disorders / liver fibrosis / vomiting / transfusion-dependent beta-thalassemia / thalassemia major / chronic iron Treatment / allergic reactions / cardiac disease / Cochrane review found dysfunction / hearing loss / acute renal failure / tinnitus / agranulocytosis / disorders / fibrosis / blood disorder / endocrine dysfunction / /

MedicalTreatment

chelation therapy / blood transfusion / /

Organization

Food and Health Bureau Hospital Authority / 47th American Society of Haematology Annual / Hospital Authority / /

Person

Prescott E et al. Br / /

Position

General / HADF classification General / /

Product

Exjade / Desferal / Deferiprone / /

Technology

http / /

URL

http /

SocialTag